

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/789,956	02/26/2004	Mary J. Bossard	SHE0081.00	5777
21968	7590 10/21/2004		EXAM	INER
NEKTAR THERAPEUTICS			MONDESI, ROBERT B	
150 INDUSTRIAL ROAD SAN CARLOS, CA 94070			ART UNIT	PAPER NUMBER
			1653	

DATE MAILED: 10/21/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/789,956	BOSSARD ET AL.			
Office Action Summary	Examiner	Art Unit			
	Robert B Mondesi	1653			
The MAILING DATE of this communic	ation appears on the cover sheet w	vith the correspondence address			
Period for Reply A SHORTENED STATUTORY PERIOD FO	D DEDI V IS SET TO EXPIRE 1 N	MONTH(S) FROM			
THE MAILING DATE OF THIS COMMUNIC  Extensions of time may be available under the provisions of after SIX (6) MONTHS from the mailing date of this commur  If the period for reply specified above is less than thirty (30)  If NO period for reply is specified above, the maximum statu  Failure to reply within the set or extended period for reply within the set or extended peri	ATION.  37 CFR 1.136(a). In no event, however, may a nication.  days, a reply within the statutory minimum of the tory period will apply and will expire SIX (6) MC ll. by statute, cause the application to become A	reply be timely filed irty (30) days will be considered timely. NTHS from the mailing date of this communication. IBANDONED (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed	on				
24/	)⊠ This action is non-final.				
· · · · · · · · · · · · · · · · · · ·	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is				
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) Claim(s) 1-61 is/are pending in the ap 4a) Of the above claim(s) is/are 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-61 are subject to restriction	e withdrawn from consideration.				
Application Papers  9) ☐ The specification is objected to by the	Examiner.				
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
Replacement drawing sheet(s) including to 11) The oath or declaration is objected to		g(s) is objected to. See 37 CFR 1.121(d). ed Office Action or form PTO-152.			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for a) All b) Some * c) None of:  1. Certified copies of the priority o	locuments have been received. locuments have been received in f the priority documents have bee al Bureau (PCT Rule 17.2(a)).	Application No en received in this National Stage			
Attachment(s)					
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)					
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  Paper No(s)/Mail Date  5) Notice of Informal Patent Application (PTO-152)  6) Other:					

Art Unit: 1653

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-30, drawn to a plurality of conjugates each conjugate having one to three water soluble polymers covalently attached to a factor VII moiety, classified in class 530, subclass 381.
- II. Claims 31-57, drawn to a composition comprising a plurality of monoPEGylated Factor VIII moiety conjugates, classified in class 530, subclass 383.
- III. Claim 58, drawn to a method for making a conjugate comprising contacting under conjugation conditions, a Factor VIII moiety with a polymeric reagent, classified in class 530, subclass 39.1.
- IV. Claims 59-61, drawn to a method of treating a patient in need of FactorVIII therapy, classified in class 514, subclass 12.

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation, different functions, and different effects. The product of invention of Group I is a plurality of conjugates with each conjugate having one to three water soluble polymers covalently

Art Unit: 1653

attached to a factor VII moiety, whereas the product of Invention of Group II is a composition comprising a plurality of monoPEGylated Factor VIII moiety conjugates.

Inventions I and III are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the process as claimed can be used with a materially different product, for example the process of conjugation can be used for conjugating antigens in order to create an immune response for the production of antibodies.

Inventions I and IV, II and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in a materially different process, such as the process of making anti bodies.

Inventions III and IV are related as process of making and process of using the product. The use as claimed cannot be practiced with a materially different product. Since the product is not allowable, restriction is proper between said method of making and method of using. The product claim will be examined along with the elected invention (MPEP § 806.05(i)).

Art Unit: 1653

The product of Invention of Group II is not used in the method of invention of Group III.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification and search, restriction for examination purposes as indicated is proper.

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See

Art Unit: 1653

"Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert B Mondesi whose telephone number is 571-272-0956. The examiner can normally be reached on 9am-5pm, Monday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Art Unit: 1653

Robert B. Mondesi Patent Examiner Group 1653

ROBERT A. WAX
PRIMARY EXAMINER

Au 1653